Viatris (VTRS)

• Market cap: $10.3B
• 1 day: -1.38%
• 5 days: -4.24%
• 1 month: -7.93%
• 3 months: -30.84%
• 6 months: -25.24%
• Year to date: -30.84%
• 1 year: -28.06%
• 5 years: -44.72%
• 10 years: -44.72%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

42% more first-time investments, than exits

New positions opened: 138 | Existing positions closed: 97

17% more funds holding in top 10

Funds holding in top 10: 12 [Q3] → 14 (+2) [Q4]

13% more capital invested

Capital invested by funds: $11B [Q3] → $12.4B (+$1.38B) [Q4]

3.91% more ownership

Funds ownership: 79.44% [Q3] → 83.34% (+3.91%) [Q4]

2% more funds holding

Funds holding: 984 [Q3] → 1,006 (+22) [Q4]

0% more call options, than puts

Call options by funds: $35M | Put options by funds: $34.9M

19% less repeat investments, than reductions

Existing positions increased: 303 | Existing positions reduced: 376

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $9 5% upside
• Avg. target: $10.50 22% upside
• High target: $13 51% upside

4 analyst ratings

• positive: 1 25%
• neutral: 1 25%
• negative: 2 50%

Jefferies Glen Santangelo 45% 1-year accuracy 5 / 11 met price target	51% upside $13	Buy Maintained	7 Mar 2025
Piper Sandler David Amsellem 55% 1-year accuracy 18 / 33 met price target	16% upside $10	Neutral Reiterated	5 Mar 2025
Barclays Balaji Prasad 30% 1-year accuracy 13 / 44 met price target	5% upside $9	Underweight Maintained	28 Feb 2025
B of A Securities Jason Gerberry 38% 1-year accuracy 8 / 21 met price target	16% upside $10	Underperform Maintained	28 Feb 2025